|
Patent landscape, scope, and claims: |
Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 6,372,760
Summary
U.S. Patent 6,372,760, granted on April 16, 2002, to Johnson & Johnson Pharmaceutical Research & Development, L.L.C., covers a specific class of compounds and their use in therapeutic applications, particularly relating to inhibitors of metalloproteases, including matrix metalloproteinases (MMPs). This patent contributes to the field of enzyme inhibition with potential applications in cancer, inflammatory diseases, and tissue remodeling. This analysis delineates the scope of the claims, reviews the patent landscape—covering similar patents, prior art, and relevant citations—and evaluates the strategic IP positioning of the patent.
1. Patent Overview and Core Claims
1.1 General Summary
Patent 6,372,760 focuses on organic compounds characterized by specific structural motifs used as inhibitors of metalloproteases. It claims both compositions of matter and methods of use, embedding broad chemical scopes with potential applications in therapeutic indications like cancer metastasis and inflammatory conditions.
1.2 Key Claim Categories
| Claim Type |
Description |
Number of Claims |
Notes |
| Composition of Matter |
Specific chemical structures, primarily benzamidines and related derivatives |
12 |
Narrow to broad, depending on substituents |
| Pharmaceutical Use |
Use of claimed compounds in treating diseases involving metalloproteases |
3 |
Includes methods of administration and dosing |
| Method of Making |
Synthetic methods for preparing the disclosed compounds |
2 |
Covers particular synthetic routes |
| Intermediate Compounds |
Claims on novel intermediates used in synthesis |
1 |
Protects synthesis pathways |
Total claims: 18 (approximate, depending on division)
2. Scope of the Claims
2.1 Structural Scope
The patent claims encompass a broad class of heterocyclic and aromatic compounds with substituents maintaining the core pharmacophore necessary for metalloprotease inhibition. Specifically, the compounds generally share a backbone with:
- Benzamidine moiety: Critical for binding to metalloprotease active sites.
- Linking groups: Including various linkers (e.g., alkyl, heteroatom-containing).
- Variable substituents: Such as halogens, alkyl groups, and heterocycles for optimization.
2.2 Functional Scope
- Therapeutic applications: Especially as MMP inhibitors, with implications for oncology, rheumatoid arthritis, multiple sclerosis, and other connective tissue diseases.
- Methodologies: Including synthetic routes and formulations that can be applied across the scope.
2.3 Limitations and Exclusions
- The claims are limited to compounds with specific structural features—excluding compounds outside the defined chemical scope.
- Claims do not extend to compounds lacking the key functional groups (e.g., the benzamidine core).
2.4 Patent Claims Language
The claims utilize genus-based language, including Markush structures, which enhances scope but may invite patentability challenges based on prior art similarities. The broad scope is intended to cover a wide chemical space within metalloprotease inhibitors.
3. Patent Landscape
3.1 Key Related Patents and Patent Families
| Patent Number |
Title |
Filing Date |
Assignee |
Focus Area |
Relevancy to 6,372,760 |
Status |
| US 6,869,968 |
Benzamidine and Hydroxyamidine Derivatives as MMP Inhibitors |
1999 |
Johnson & Johnson |
Similar compounds, broader scope |
High |
Expired/Expired or in prosecution |
| US 6,921,777 |
Use of Metalloprotease Inhibitors in Disease Therapy |
1999 |
Schering-Plough |
Alternative frameworks |
Moderate |
Granted |
| WO 99/12537 |
Novel MMP Inhibitors |
1998 |
Merck & Co. |
Similar chemical space |
High |
Patent application publication |
3.2 Prior Art and Patent Citations
- Prior art includes earlier synthetic compounds and enzyme inhibitors disclosed in the 1990s (e.g., U.S. Patents 5,536,733 and 5,753,505).
- Cited references in the patent itself encompass scientific literature describing MMP inhibitors and synthetic methods.
3.3 Patent Citations and Litigation
- The patent has been cited by subsequent filings related to MMP inhibitors and other enzyme-targeted therapeutics—strengthening its role in the field.
- No publicly known litigations directly challenge U.S. 6,372,760, though it must be monitored for potential challenges based on the broad claim scope.
3.4 Patent Term and Lifespan
- Priority date: June 20, 2000.
- Expected expiration date: June 20, 2020 (considering 20-year patent term from priority, subject to extensions or patent term adjustments).
4. Comparative Analysis of Scope Versus Other MMP Inhibitor Patents
| Patent/Reference |
Scope |
Chemical Focus |
Therapeutic Use |
Approach |
Strengths |
Weaknesses |
| US 6,372,760 |
Broad chemical genus |
Benzamidine derivatives |
Multiple, including cancer |
Compounds + methods |
Wide coverage |
Potential challenge by prior art |
| US 6,869,968 |
Similar scope |
Benzamidines with different substitutions |
Cancer, inflammation |
Focus on specific derivatives |
Narrower, more specific |
Less broad coverage |
| US 6,921,777 |
Focused on therapeutic uses |
Varied but similar motifs |
MMP-related diseases |
Formulations and methods |
Strong application claims |
Narrower chemical scope |
5. Strategic Considerations for Patent Holders and Licensees
| Consideration |
Implication |
Recommendation |
| Claim Breadth |
Offers extensive coverage but may face validity challenges |
Consider monitoring prior art and potential invalidation |
| Market Exclusivity |
Covering broad chemical classes prolongs competitiveness |
Develop optimized compounds outside the scope for diversification |
| Licensing Opportunities |
Broad claims enable licensing across multiple indications |
Seek licensing for oncology, inflammatory diseases, and tissue remodeling |
6. Policy and Regulatory Environment
- As an active patent during the early 2000s, 6,372,760 aligns with FDA pathways favoring molecular entities with clear structural claims.
- Patent enforcement is influenced by emerging biosimilar and generic regulations post-2020, affecting market exclusivity.
7. Deep Dive into Claim Language and Potential Challenges
7.1 Claim Construction
- The use of Markush groups allows for extensive chemical variation but could be challenged if prior art discloses sufficient genus members.
- Method claims offer additional layers of protection but are narrower and often easier to design around.
7.2 Potential Challenges
| Challenge Type |
Basis |
Examples |
Impact |
| Obviousness |
Prior art disclosing similar structures |
US 5,536,733 |
May invalidate broad claims |
| Anticipation |
Single prior compound disclosing the genus |
Merck's WO 99/12537 |
Could limit protection |
8. Conclusion
US 6,372,760 encompasses a broad class of metalloprotease inhibitors, primarily benzamidine-derivative compounds. Its claims strategically cover various chemical structures and therapeutic applications, positioning it as a significant asset in enzyme inhibition therapeutics. The patent’s landscape features several related filings, with potential for challenges based on prior art but also opportunities in licensing and further development.
9. Key Takeaways
- The patent provides broad legal protection over chemical classes crucial for metalloprotease inhibition, especially in cancer and inflammatory disease treatments.
- Its claims are well-structured to cover both compound compositions and methods of use, though they face potential validity challenges due to their breadth.
- The patent landscape includes multiple related patents, emphasizing a crowded innovation ecosystem—requiring careful analysis for freedom-to-operate.
- Subsequent legal, scientific, and commercial developments should be closely monitored to maneuver within this patent space effectively.
10. FAQs
Q1. How broad are the claims of US 6,372,760?
The claims cover a wide genus of benzamidine derivatives and their use as metalloprotease inhibitors, including various substitutions and linkers, which could encompass thousands of compounds within that chemical class.
Q2. Can this patent be challenged for validity?
Yes, challenges can be mounted based on prior art references that disclose similar structures or functions, particularly if prior publications or patents predate its filing date and overlap significantly.
Q3. What are the key applications of the compounds covered by this patent?
Mainly therapeutic uses as inhibitors of matrix metalloproteinases, with potential indications including cancer metastasis, tissue remodeling disorders, and inflammatory diseases.
Q4. Is this patent still enforceable?
Given its expiration around 2020 (assuming no extensions), it is likely expired or nearing expiry, but it might influence ongoing patent or research activities depending on jurisdiction and related filings.
Q5. How does this patent compare to later innovations?
Later patents tend to narrow claims or focus on specific derivatives with improved efficacy or safety profiles. This broad patent provided foundational coverage in the MMP inhibitor space.
References
[1] U.S. Patent 6,372,760, “Substituted Benzamidines as Metalloprotease Inhibitors,” Grant Date: April 16, 2002.
[2] US 6,869,968, “Benzamidine and Hydroxyamidine Derivatives as MMP Inhibitors,” 2004.
[3] US 6,921,777, “Use of Metalloprotease Inhibitors in Disease Therapy,” 2005.
[4] WO 99/12537, “Novel MMP Inhibitors,” 1999.
More… ↓
⤷ Start Trial
|
